Protein tyrosine phosphatase PTPN1 modulates cell growth and associates with poor outcome in human neuroblastoma

Diagnostic Pathology

Table 2 Immunostaining of PTPs from NB tissue sections

Patients (n = 44)	%	PTPN1		PTPRH		PTPRZ1		PTEN
Patients (n = 44)	%	high	low/no	high	low/no	high	low/no	high	low/no
Gender		(p = 0.3179) (R = 0.155)		(p = 0.571) (R = 0.068)		(p = 0.832) (R = 0.032)		(p = 0.4475) (R = 0.115)
Male (21)	48	8	11	17	3	17	3	19	2
Female (23)	52	6	16	18	5	19	4	19	4
Age at diagnosis (months)		(p = 0.691) (R = 0.62)		(p = 0.243) (R = -0.178)		(p = 0.525) (R = -0.097)		(p = 0.376) (R = -0.133)
< 18 (29)	66	9	19	25	4	25	4	26	3
> 18 (15)	34	8	5	10	4	11	3	12	3
MYCN		(p = 0.2551) (R = 0.204)		(p = 0.1036) (R = 0.283)		(p = 0.3719) (R = -0.155)		(p = 0.9699) (R = -0.007)
Amplified (8)	18	4	3	5	3	6	0	7	1
Non-amplified (25)	57	8	16	22	3	22	3	22	3
Risk		(p = 0.013) (R = 0.394)		(p = 0.023) (R = -0.348)		(p = 0.241) (R = -0.179)		(p = 0.448) (R = -0.115)
Intermediate, high(23)	52	10	11	15	7	17	5	19	4
Low (21)	48	3	17	20	1	2	19	19	2
Stage		(p = 0.047) (R = 0.310)		(p = 0.079) (R = 0.268)		(p = 0.335) (R = 0.147)		(p = 0.530) (R = 0.095)
Metastatic (12)	27	6	4	7	4	9	3	11	1
Non-metastatic (32)	73	8	23	28	4	27	4	27	5
Stage		(p = 0.008) (R = 0.414)		(p = 0.101) (R = .250)		(p = 0.735) (R = -0.052)		(p = 0.234) (R = 0.179)
III, IV (17)	39	9	6	11	5	13	3	16	1
non-III, non-IV (27)	61	5	21	24	3	23	4	22	5
Stage		(p = 0.095) (R = 0.260)		(p = 0.001) (R = -0.502)		(p = 0.059) (R = -0.287)		(p = 0.827) (R = -0.033)
IV (13)	30	6	5	6	6	8	4	11	2
non-IV (31)	70	8	22	29	2	28	3	27	4
Survival		(p = 0.824) (R = 0.159)		(p = 0.2016) (R = -0.195)		(p = 0.1191) (R = -0.238)		(p = 0.505) (R = -0.101)
Dead (10)	23	3	5	6	3	6	3	8	2
Alive (34)	77	11	22	29	5	30	4	30	4

PTP immunostaining was not obtained in some cases due to lack of tissue to perform the analysis or to non-informative immunostaining results
Significant p values (p < 0.05) are in bold

ISSN: 1746-1596